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Global (Q)SAR models on substrates for 
human Cytochrome P450 3A4  
The aim of this study was to develop QSAR 
predictions for identifying CYP3A4 substrates and 
non-substrates in the EINECS chemicals (European 
INventory of Existing Commercial chemical 
Substances).
Introduction
The CYP3A subfamily plays a dominant role by the elimination of 
around 35% of prescribed drugs. It has a broad catalytic selectivity and 
metabolises among others drugs, steroids, carcinogens and pesticides. 
The substrates range in size from small molecules e.g. acetaminophen 
(151 g/mol) to relatively big molecules such as Cyclosporin A (1203 
g/mol).
Besides helping with the excretion of exogenous compounds CYP3A4
has also shown to transform protoxicans into their toxic structure. An
example is Aflatoxin B1 (AFB1) which needs to be transformed before it
can function as a hepatic carcinogen. CYP3A4 metabolise AFB1 and
produces both genotoxic and non-genotoxic metabolites.
Materials and Methods
Modelling methodology
MultiCASE Groups the chemicals by structure (2-10 interconnected
non-hydrogen atoms) and performs multiple linear regression on these
groups. A modulator (e.g. activating fragments, inactivating fragments,
logKow, molecular orbital energies) is used in each linear regression as
independent variable and the activity as the dependent variable.
Leadscope The chemicals are classified by structural features into
categories e.g. functional groups, heterocycles, pharmacophores and
logKow. The important structural features are then used in a partial least
squares (PLS) model. The PLS model reduces the number of structural
features and these features are used as the independent variables in a
logistic regression.
SciQSAR The linear parametric discriminant analysis was used. 86
physical-chemical descriptors were used as independent variables. The
variables describe e.g. electron accessibility, the skeletal branching and
logKow.
Data
•The training set consists of experimental human data on 863
chemicals1,2,3,4 . 503 positive and 360 negative as CYP3A4 substrates.
•40,0374 EINECS chemicals (European INventory of Existing
Commercial chemical Substances).
Results
1: Leave 50% out cross-validation were performed 3 times
2: LOO cross-validation was performed
Discussion
25% - 66% of the EINECS chemicals were predicted as CYP3A4
substrates. SciQSAR predicts the double amount of CYP3A4
substrates in the EINECS chemicals compared to MultiCASE and
Leadscope. The actual number of CYP3A4 substrates in the EINECS
chemicals is therefore still difficult to approximate. However, since
35% of prescribed drugs are metabolised by CYP3A4, the predictions
by MultiCASE and Leadscope which say that 25-33% of EINECS
chemicals are metabolized by CYP3A4 can be considered to be
realistic. The number of CYP3A4 substrates is most likely
overestimated in the SciQSAR model.
Conclusion
The models produced by Leadscope and MultiCASE can be used to
predict CYP3A4 substrates in untested chemicals and identify potential
toxicity concerns due to exposure to environmental chemicals.
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Mean and range results for cross-validation
Sensitivity
(correct pos) 
Specificity
(correct neg) 
Concordance
(correct total) 
MultiCASE1 68.1
67.4-68.9
52.1
51.5-53.0
61.5
60.8-62.3
Leadscope1 78.9
77.9-79.5
61.6
59.7-63.3
71.7
71.1-72.8
SciQSAR2 75.7 48.3 64.3
Predictions for EINECS chemicals
In domain
[%]
In domain and predicted to be a substrate
[%]
MultiCASE 49 33
Leadscope 34 25
SciQSAR 100 66
